Matthew Painschab, MD (IMAGE)

UNC Lineberger Comprehensive Cancer Center

Matthew Painschab, MD

Caption

UNC LIneberger's Matthew Painschab, MD, and colleagues report in Lancet Global Health that they have demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective.

Credit

UNC School of Medicine

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.